LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

NVO

56.36

-0.23%↓

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

NVO

56.36

-0.23%↓

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

NVO

56.36

-0.23%↓

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

NVO

56.36

-0.23%↓

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

NVO

56.36

-0.23%↓

Search

Stryker Corp

Gesloten

SectorGezondheidszorg

389.64 -0.43

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

385.47

Max

391.32

Belangrijke statistieken

By Trading Economics

Inkomsten

884M

1.5B

Verkoop

156M

6B

K/W

Sectorgemiddelde

51.842

35.733

EPS

3.13

Dividendrendement

0.85

Winstmarge

25.54

Werknemers

53,000

EBITDA

634M

1.5B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+11.33% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.85%

3.13%

Volgende Winsten

28 okt 2025

Volgende dividenddatum

31 okt 2025

Volgende Ex Dividend datum

30 sep 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-3.5B

150B

Vorige openingsprijs

390.07

Vorige sluitingsprijs

389.64

Nieuwssentiment

By Acuity

35%

65%

111 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Stryker Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 jul 2025, 20:42 UTC

Winsten

Stryker Lifts Guidance on Improving Tariff Outlook

1 mei 2025, 20:56 UTC

Winsten

Stryker Lowers Adjusted EPS View on $200 Million Tariff Impact

28 jan 2025, 21:55 UTC

Winsten

Stryker Sees Further Organic Sales Growth in 2025

28 jan 2025, 21:46 UTC

Acquisities, Fusies, Overnames

Stryker to Sell Spinal Implants Business to Viscogliosi Brothers

31 jul 2025, 20:09 UTC

Winsten

Stryker Estimates Net Impact From Tariffs in 2025 of Approximately $175M

31 jul 2025, 20:09 UTC

Winsten

Stryker Sales >SYK

31 jul 2025, 20:09 UTC

Winsten

Stryker Sees FY25 Organic Net Sales Up 9.5%-10%

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q Sales $6B >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q Net $884M >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker Sees FY Adj EPS $13.40-Adj EPS $13.60 >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q EPS $2.29 >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q Adj EPS $3.13 >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q Sales $6B >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q EPS $2.29 >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q EPS $2.29 >SYK

1 mei 2025, 20:41 UTC

Winsten

Stryker Lowers Adjusted EPS View on $200M Tariff Impact

1 mei 2025, 20:11 UTC

Winsten

Stryker Cuts FY25 View To Adj EPS $13.20-Adj EPS $13.45 >SYK

1 mei 2025, 20:10 UTC

Winsten

Stryker Raising FY25 Organic Net Sales Growth Guidance Range to 8.5% to 9.5% >SYK

1 mei 2025, 20:05 UTC

Winsten

Stryker 1Q Adj EPS $2.84 >SYK

1 mei 2025, 20:05 UTC

Winsten

Stryker 1Q Net $654M >SYK

1 mei 2025, 20:05 UTC

Winsten

Stryker 1Q EPS $1.69 >SYK

1 mei 2025, 20:05 UTC

Winsten

Stryker 1Q Sales $5.87B >SYK

1 mei 2025, 20:05 UTC

Winsten

Stryker 1Q EPS $1.69 >SYK

19 feb 2025, 13:53 UTC

Acquisities, Fusies, Overnames

Stryker Files 8K - Asset Acquisition Or Disposition >SYK

19 feb 2025, 13:30 UTC

Acquisities, Fusies, Overnames

Stryker Completes Acquisition Of Inari Medical, Inc., Providing Entry Into The High-growth Peripheral Vascular Segment >SYK

28 jan 2025, 21:09 UTC

Acquisities, Fusies, Overnames

Stryker: Transaction Is Expected to Close in the U.S. in 1H 2025 >SYK

28 jan 2025, 21:09 UTC

Acquisities, Fusies, Overnames

Stryker: Agreement Includes Binding Offer to Acquire Stryker's Spinal Implants Business in France >SYK

28 jan 2025, 21:08 UTC

Acquisities, Fusies, Overnames

Stryker: After Closing, VB Spine Will Become a Strategic Partner to Stryker With Exclusive Access to Mako Spine and Copilot for Use With VB Spine's Implants in Spine Procedures >SYK

28 jan 2025, 21:08 UTC

Acquisities, Fusies, Overnames

Stryker: Agreement to Sell U.S. Spinal Implants Business to Viscogliosi Brothers, LLC to Create Newly Formed Co Called VB Spine, LLC >SYK

28 jan 2025, 21:06 UTC

Winsten

Stryker Sees Organic Net Sales Growth of 8% to 9% for 2025 >SYK

Peer Vergelijking

Prijswijziging

Stryker Corp Prognose

Koersdoel

By TipRanks

11.33% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 435.77 USD  11.33%

Hoogste 456 USD

Laagste 407 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor Stryker Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

16 ratings

13

Buy

3

Hold

0

Sell

Technische score

By Trading Central

373.92 / 383.99Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

111 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Stryker Corp

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.